Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

673
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
673
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

42
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
42
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Declines in Social Support During Breast Cancer Treatment and Their Association With Exercise Capacity Reductions in Breast Cancer Survivors.

American journal of lifestyle medicine·2026
Same author

Cardiac remodelling and dysfunction in cancer patients receiving cardiotoxic therapies: proteomic and metabolomic profiling.

European heart journal·2026
Same author

Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax: A Multicenter Cohort Study.

JACC. Advances·2026
Same author

Atrial Fibrillation Risk and Cardiovascular Events After Hematopoietic Cell Transplantation: A Prospective Cohort Study.

JACC. CardioOncology·2026
Same author

In Memoriam: Dr Eugene Braunwald, MD, MACC.

JACC. CardioOncology·2026
Same author

STING promotes CD8 T-cell cardiotropism and fibrosis from distinct cellular compartments in doxorubicin cardiomyopathy.

Cardiovascular research·2026

Related Experiment Video

Updated: Sep 9, 2025

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.5K

Atorvastatin and left atrial function during anthracycline-based chemotherapy.

Vencel Juhasz1, Zsofia D Drobni2, Thiago Quinaglia3

  • 1Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance
|August 28, 2025
PubMed
Summary

Atorvastatin did not prevent left atrial strain decline in lymphoma patients receiving anthracyclines. This study found no significant difference in left atrial function between atorvastatin and placebo groups.

Keywords:
Cancer therapy-related cardiac dysfunctionCardiac dysfunctionCardiac magnetic resonanceFeature trackingMyocardial strain

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.4K

Related Experiment Videos

Last Updated: Sep 9, 2025

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.5K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.4K

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Left atrial (LA) structural and functional abnormalities are linked to adverse outcomes in heart disease.
  • The impact of anthracyclines on LA structure and function is not fully understood.
  • Atorvastatin's protective effect on left ventricular ejection fraction against anthracyclines is known, but its effect on the LA is unclear.

Purpose of the Study:

  • To investigate whether atorvastatin mitigates anthracycline-induced impairment of left atrial (LA) structure and function.
  • To evaluate the effect of atorvastatin on LA strain and volumetric measurements in patients undergoing anthracycline chemotherapy.

Main Methods:

  • The STOP-CA randomized clinical trial enrolled lymphoma patients treated with anthracyclines.
  • Participants were randomized to receive either placebo or atorvastatin for 12 months.
  • Cardiovascular magnetic resonance (CMR)-derived LA volumetric and functional measurements, including global longitudinal strain (GLS), were assessed at baseline and 12 months using feature tracking.

Main Results:

  • No significant difference was observed in the proportion of participants experiencing a ≥1SD or ≥20% relative decrease in LA GLS between the atorvastatin and placebo groups.
  • A decrease in LA GLS was noted in the placebo group from baseline to follow-up.
  • Participants over 50 years old showed a greater relative decrease in LA GLS with anthracyclines, irrespective of atorvastatin treatment.

Conclusions:

  • Atorvastatin did not attenuate the decline in CMR-derived LA GLS in lymphoma patients treated with anthracycline-based chemotherapy.
  • The study suggests that atorvastatin does not protect against anthracycline-associated impairment of left atrial function.